Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016
Published Nov 16, 2016
168 pages — Published Nov 16, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) Pipeline Review, H2 2016, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 13, 6, 9 and 2 respectively.Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD).

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline gu

  
Source:
Document ID
GMDHC8665IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview101
Therapeutics Development112
  Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview111
  Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Comparative Analysis121
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics under Development by Companies132
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline Products Glance154
  Late Stage Products151
  Clinical Stage Products161
  Early Stage Products171
  Unknown Stage Products181
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Products under Development by Companies192
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Companies Involved in Therapeutics Development2126
  AnGes MG, Inc.211
  AstraZeneca Plc221
  Athera Biotechnologies AB231
  Athersys, Inc.241
  Bayer AG251
  Betagenon AB261
  BiogenCell Ltd.271
  CardioVascular BioTherapeutics, Inc.281
  Celgene Corporation291
  Diffusion Pharmaceuticals Inc301
  Hemostemix Ltd311
  ID Pharma Co., Ltd.321
  Juventas Therapeutics, Inc.331
  LipimetiX Development Inc341
  miRagen Therapeutics, Inc.351
  Nuo Therapeutics, Inc.361
  Proteon Therapeutics, Inc.371
  Recardio GmbH381
  Resverlogix Corp.391
  Sigma-Tau S.p.A.401
  Stemedica Cell Technologies, Inc.411
  Symic Biomedical, Inc.421
  Theravasc, Inc.431
  VESSL Therapeutics Ltd441
  ViroMed Co Ltd451
  Yuyu Pharma, Inc.461
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Assessment479
  Assessment by Monotherapy Products471
  Assessment by Target482
  Assessment by Mechanism of Action502
  Assessment by Route of Administration522
  Assessment by Molecule Type542
Drug Profiles5696
  ACP-01 Drug Profile563
  AEM-28 Drug Profile592
  ALD-301 Drug Profile612
  alprostadil Drug Profile631
  Annexin A-5 Drug Profile641
  apabetalone Drug Profile659
  BAY-1193397 Drug Profile741
  BC-1 Drug Profile751
  beperminogene perplasmid Drug Profile766
  CVBT-141C Drug Profile821
  DVC-10101 Drug Profile831
  ELS-140 Drug Profile841
  JVS-100 Drug Profile855
  levocarnitine propionate hydrochloride Drug Profile901
  MGN-6114 Drug Profile911
  MultiGeneAngio Drug Profile921
  O-304 Drug Profile932
  PC-mAb Drug Profile952
  PDA-002 Drug Profile971
  PF-05285401 Drug Profile9810
  REC-03 Drug Profile1081
  Rejuveinix Drug Profile1091
  rivaroxaban Drug Profile11014
  SB-030 Drug Profile1242
  sodium nitrite SR Drug Profile1262
  Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology Drug Profile1286
  transcrocetinate sodium Drug Profile1344
  TXA-127 Drug Profile1383
  V-10 Drug Profile1411
  VM-202 Drug Profile1423
  vonapanitase Drug Profile1454
  YY-984 Drug Profile1491
  zibotentan Drug Profile1502
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Dormant Projects1524
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Discontinued Products1561
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Product Development Milestones15710
  Featured News &Press Releases1571
    Oct 25, 2016: Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference1571
    Oct 20, 2016: Dr. Jackie R. See M.D. Joins AngioSoma, Scientific Advisory Board1571
    Oct 20, 2016: Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors1581
    Oct 11, 2016: AngioSoma Files 3 New Patent Applications on Liprostin1581
    Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada1591
    Sep 29, 2016: Low levels of endogenous anti-PC identified as a novel risk factor for vein bypass graft failure and cardiovascular complications in PAD patients1591
    Sep 28, 2016: Athera presents positive First-in-Patient data with their new antibody against immunovascular disease at ESVS1601
    Aug 11, 2016: Athera Biotechnologies completes First-in-Patient Study with New Antibody Against Immunovascular Disease1601
    May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis &Transplant Association Congress (ERA-EDTA)1611
    Apr 13, 2016: Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease1621
    Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease1621
    Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 20151631
    Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease1641
    Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor1651
    Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease1652
Appendix1672
  Methodology1671
  Coverage1671
  Secondary Research1671
  Primary Research1671
  Expert Panel Validation1671
  Contact Us1671
  Disclaimer1681

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016" Nov 16, 2016. Alacra Store. May 18, 2024. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Peripheral-Arterial-Disease-PAD-Peripheral-Vascular-Disease-PVD-Pipeline-Review-H2-2016-2088-16823>
  
APA:
Global Markets Direct - Market Research. (2016). Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2016 Nov 16, 2016. New York, NY: Alacra Store. Retrieved May 18, 2024 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Peripheral-Arterial-Disease-PAD-Peripheral-Vascular-Disease-PVD-Pipeline-Review-H2-2016-2088-16823>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.